Omeros (NASDAQ:OMER) has been given a $24.00 target price by analysts at Maxim Group in a research note issued on Tuesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s target price would suggest a potential upside of 24.22% from the stock’s current price.

Several other analysts have also weighed in on OMER. HC Wainwright set a $30.00 target price on shares of Omeros and gave the company a “buy” rating in a research note on Wednesday, November 29th. Zacks Investment Research lowered shares of Omeros from a “buy” rating to a “hold” rating in a research note on Wednesday, October 25th. Cantor Fitzgerald reiterated a “hold” rating and set a $19.00 target price (up previously from $15.00) on shares of Omeros in a research note on Thursday, August 24th. Cowen lowered shares of Omeros from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 2nd. Finally, Wedbush reiterated an “outperform” rating and set a $47.00 target price on shares of Omeros in a research note on Tuesday, November 28th. Five investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Omeros presently has a consensus rating of “Buy” and an average target price of $34.14.

Omeros (NASDAQ OMER) traded up $0.42 on Tuesday, reaching $19.32. 518,700 shares of the company traded hands, compared to its average volume of 798,504. The company has a debt-to-equity ratio of 8.99, a quick ratio of 4.74 and a current ratio of 4.77. Omeros has a 1 year low of $8.71 and a 1 year high of $27.09.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.18. The company had revenue of $21.66 million during the quarter, compared to analyst estimates of $17.82 million. The company’s revenue was up 91.9% on a year-over-year basis. During the same period in the prior year, the company earned ($0.34) earnings per share. equities research analysts anticipate that Omeros will post -0.98 EPS for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in OMER. Legal & General Group Plc grew its position in shares of Omeros by 7.8% during the second quarter. Legal & General Group Plc now owns 10,359 shares of the biopharmaceutical company’s stock worth $208,000 after acquiring an additional 751 shares during the last quarter. Rhumbline Advisers grew its position in shares of Omeros by 1.8% during the second quarter. Rhumbline Advisers now owns 46,632 shares of the biopharmaceutical company’s stock worth $928,000 after acquiring an additional 832 shares during the last quarter. Schwab Charles Investment Management Inc. grew its position in shares of Omeros by 1.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 197,665 shares of the biopharmaceutical company’s stock worth $3,935,000 after acquiring an additional 2,548 shares during the last quarter. Voya Investment Management LLC grew its position in shares of Omeros by 20.7% during the second quarter. Voya Investment Management LLC now owns 19,300 shares of the biopharmaceutical company’s stock worth $384,000 after acquiring an additional 3,304 shares during the last quarter. Finally, Tocqueville Asset Management L.P. grew its position in shares of Omeros by 0.7% during the third quarter. Tocqueville Asset Management L.P. now owns 480,896 shares of the biopharmaceutical company’s stock worth $10,397,000 after acquiring an additional 3,430 shares during the last quarter. Hedge funds and other institutional investors own 49.85% of the company’s stock.

WARNING: This report was originally posted by Daily Political and is owned by of Daily Political. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.dailypolitical.com/2017/12/14/omeros-omer-pt-set-at-24-00-by-maxim-group.html.

Omeros Company Profile

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.